Loading...
Loading...
India's ibrutinib imports from JAPAN total $15.5K across 1 shipments from 1 foreign suppliers. SPRING BIO SOLUTION PTE LTD leads with $15.5K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MYLAN LABORATORIES LIMITED. This corridor reflects India's pharmaceutical import demand for ibrutinib — a concentrated sourcing relationship with select suppliers from JAPAN.

SPRING BIO SOLUTION PTE LTD is the leading Ibrutinib supplier from JAPAN to India, with import value of $15.5K across 1 shipments. The top 5 suppliers — SPRING BIO SOLUTION PTE LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SPRING BIO SOLUTION PTE LTD | $15.5K | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED | $15.5K | 1 | 100.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Ibrutinib suppliers from JAPAN to India include SPRING BIO SOLUTION PTE LTD. The leading supplier is SPRING BIO SOLUTION PTE LTD with import value of $15.5K USD across 1 shipments. India imported Ibrutinib worth $15.5K USD from JAPAN in total across 1 shipments.
India imported Ibrutinib worth $15.5K USD from JAPAN across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Ibrutinib sourced from JAPAN include MYLAN LABORATORIES LIMITED. The largest buyer is MYLAN LABORATORIES LIMITED with $15.5K in imports across 1 shipments.
The total value of Ibrutinib imports from JAPAN to India is $15.5K USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists